Overview

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin. The typical chemotherapy treatment is Carboplatin and Paclitaxel.

Phase:

Phase 1

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Bristol-Myers Squibb

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Ipilimumab
Nivolumab
Paclitaxel